INTRODUCTION
Fragile X syndrome (FXS) is the most common heritable form of intellectual disability and autism, found in 1 in 4000 in males and 1 in 8000 in females in the general populaiton, reviewed in [Hagerman et al., 2009] . FXS usually results from CGG repeat expansion > 200, termed 'full mutation' (FM), subsequent methylation of the regulatory regions and silencing of the FMR1 gene located on the X chromosome [Godler et al., 2010] . Fragile X associated tremor/ataxia syndrome (FXTAS) is a 'late-onset' neurodegenerative disorder affecting carriers of the CGG expansion between 55 and 199 repeats, termed premutation (PM) [Jacquemont et al., 2004] . These PM alleles have estimated frequencies of 1 in 468 males and 1 in 151 females in the general population, and are associated with overexpression of the FMR1 gene and toxicity from excessive RNA production leading to cell death contributing to FXTAS pathology, reviewed in [Hagerman et al., 2009] . Probable FXTAS has also been described in FM males with an unmethylated FMR1 promoter region (UFM), resulting in active FMR1 gene and IQ greater than 70 Santa Maria et al., 2013] . Here we present a case of one FXS male with clinical features consistent with probable FXTAS first manifesting in his early 30s. We show that he has unmethylated as well as methylated FM alleles, tissue mosaicism for the size of his expanded FMR1 alleles and a de novo microdeletion in the FMR1 promoter involving complete loss of the CGG expansion.
CLINICAL REPORT

Clinical History and Sample Processing
At 5 years of age, this male was diagnosed with FXS based on morphological features and cytogenetic testing showing 40% of cells expressing the Xq27.3 fragile site. At 33 years of age he was referred to the neurology service for assessment of progressive unsteadiness developing over 18 months. There was no accompanying weakness or sensory disturbance.
His physical examination revealed mildly increased tone in all limbs, no tremor, mild symmetrical proximal weakness in the lower limbs and moderate midline ataxia. 20 ml of peripheral blood was collected in EDTA tubes for CGG sizing, methylation and FMR1 mRNA analyses. Buccal samples were also collected using the Master Amp Buccal Swab Brush kit (Epicentre technologies, USA). DNA was extracted from 15ml of blood and from buccal brush samples using the NucleoSpin®Tissue genomic DNA extraction kit (Machery-Nagel, Germany). 5 ml of blood was used for peripheral blood mononuclear cell (PBMC) isolation using Ficoll gradient separation [Loesch et al., 2011] . RNA was extracted from the isolated PBMCs using RNeasy kit (Qiagen Global) as per the manufacturer's instructions.
FMR1 Methylation, mRNA, CGG and Proximal Region sizing/copy number changes.
CGG repeat sizing in all samples was performed using polymerase chain reaction (PCR) as previously described [Khaniani et al., 2008] . The AmplideX™ FMR1 PCR Kit was used to perform CGG sizing on and determine mean methylation at two HpaII sites, 5' and 3' of the CGG expansion using blood DNA as per manufacturer's instructions (Asuragen, Texas, USA). Methylation sensitive Southern blot was used to determine CGG size and methylation of the FMR1 CpG island 5' of the CGG expansion. Appropriate normal CGG size, PM and FM DNA samples used in a previous publication [Godler et al., 2010] were included as methylation controls. Seven to 9g of DNA were digested with either methylation sensitive enzyme combination of NruI/HindIII or EagI/ EcoRI or PstI which is not sensitive to methylation changes (Figure 1 ). P32 labelled Pfxa3a probe (PCR Dig Synthesis kit; Roche Diagnostics Global) was used to detect FMR1 alleles by autoradiography as previously described [Godler et al., 2010] , with the PS8 control probe used for the PstI digestion. Hwang et al. Page: 5 FREE1 and FREE2 PCR products were synthesised using primers and conditions previously described [Godler et al., 2010] , and sized using capillary electrophoresis to rule out presence of the deletion at the 5' epigenetic boundary of the FMR1 promoter and the exon1/intron 1 boundary at the 3'end of the FMR1 promoter (Figure 1 ). The Sequenom MALDI-TOF MS EpiTYPER system (Sequenom, USA) was used to analyse mean methylation of the FREE2 region located 3' of the CGG repeat in blood, buccal and saliva samples, as previously described [Godler et al., 2010] . Two and a half million probe based microarray analysis was performed using blood DNA, to rule out large pathogenic copy number changes other than within FMR1, as well as to examine copy number changes of SNPs proximal to the CGG expansion, as previously described [Motoike et al., 2014] . FMR1 mRNA was reverse-transcribed in two separate cDNA reactions and each cDNA sample was analysed using real time-PCR reactions, as previously described [Loesch et al., 2011] .
Clinical assessments
Blood tests, including thyroid function tests, vitamin B12 and autoimmune antibody panel, were within normal limits. Nerve conduction studies performed at the time did not reveal any evidence of peripheral neuropathy. MRI of his brain and spine revealed normal cerebellum without white matter lesions in the middle cerebellar peduncles and diffuse but non-specific T2 hyperintensities in the supratentorial cerebral white matter ( Figure 2 ) that were stable on repeat imaging 9 months later despite development of spastic paraparesis in the intervening period. These radiological findings and the gait ataxia met the diagnostic criteria for probable FXTAS [Loesch et al., 2005] . He was referred to a clinical geneticist to explore the possible presence of PM and unmethylated FM alleles.
At 35 years of age formal psychological assessment for this male was also performed. 
Testing for Causes of Ataxia
Friedreich's ataxia (FA) and Spinocerebellar Ataxias (SCA) repeat regions were examined using PCR and gel electrophoresis, as previously described protocols [Biros et al., 1998; Campuzano et al., 1996] . Furthermore, omni2.5-8 microarray was used to identify no copy number changes associated with whole exon deletions/duplications in the known ataxia or neuropathy genes, based on average probe density [Motoike et al., 2014] .
RESULTS AND DISCUSSION
CGG sizing and detection of microdeletion
Southern blot FMR1 CpG island methylation analysis in blood showed unmethylated fragments between 2.5 and 4.5 Kb for NruI/HindIII digestion and 2.6 to 4.4 Kb for EagI/EcoRI digestion ( Figure 1A ). There were also methylated fragments between 4.7 and 6. (Figure 1 A and B) . The presence of FM alleles within this size range was further confirmed by the PstI digestion based Southern blot in buccal DNA ( Figure 1C ).
All three digests followed by Southern blot also detected a fragment that was ~0.2Kb
smaller than that in normal controls. This smaller allele was exclusively unmethylated and absent from the patient's mother's blood, the mother herself being a mosaic of PM and FM alleles ( Figure 1C ). The absence of the smaller allele in the mother suggested that the proband is mosaic for a de novo microdeletion and FM expansion. As the same smaller band was detected in all 3 digests, a microdeletion would have to be located within PstI/PstI fragment and also within the overlapping NruI/HindIII and EagI/EcoRI fragments (Figure 1 A). Within this PstI fragment, the microdeletion is unlikely to occur within the exon 1 or intron 1 of FMR1 as microarray SNP copy number proximal to the repeat within intron 1 and PCR amplicon sizing of the FREE2 region on the exon1/intron 1 boundary were both completely normal (Figure 1 A and D) . In this context, it is important to note that microarray SNP analysis did not identify any pathogenic variants elsewhere in the genome and the amplicon size of FREE1 located at the 5'end of the FMR1 promoter was also completely normal (Figure 1 D) . This microdeletion must therefore involve complete loss of the CGG expansion together with a proximal binding site of one of the Amplidex PCR primers as the microdeletion was not detected using AmplideX PCR (Figure 1 E) . Furthermore, this microdeletion must include loss of the Amplidex primer binding site located within the CpG island located ~87 bp 5'of the CGG repeat, as in a previous case [Schmucker et al., 1996] .
Discordance between Southern blot and AmplideX PCR CGG sizing.
Unmethylated PM alleles of ~70 repeats were detected by Southern blot following
NruI/HindIII and EagI/EcoRI digests, as indicated by the lower points of smears of ~2.9Kb and 3.0Kb in size, respectively (Fig 1B) . However, PM alleles were not detected using Hwang et al. Page: 8 AmplideX PCR or standard sizing PCR [Khaniani et al., 2008] , the latter having primer binding sites proximal to those of AmplideX. Only partially methylated FM size alleles were detected using AmplideX PCR. This discordance is unlikely to be due to the sizing imprecision of our Southern blot analyses ( +/-30 CGG repeats) as an extended Southern blot smear is still within the PM range. An alternative explanation could be microdeletion involving both a portion of CGG repeat and the Amplidex primer binding site, similar to the the smaller ~2.5kb Southern blot band that was also undetected using AmplideX PCR.
Discordance between Southern blot and Amplidex PCR methylation analysis.
Two prominent FM allele types were detected in blood, buccal and saliva DNA using Amplidex PCR ( Figure 2E ). These alleles were also identified by Southern blot after (Figure 1 ). The mean Amplidex HpaII methylation estimate was ~60% in blood and saliva and 94% in buccal DNA ( Figure 1E ). In contrast, NruI and EagI methylation values were only 11% and 12%, respectively for Southern blot (100 X density of all methylated bands/total of unmethylated and methylated bands) ( Figure 1B) . If the density of the ~2.5Kb microdeletion band is not taken out of this calculation (as AmplideX does not detect it), NruI and EagI methylation values increase to 28% and 26%, respectively. This discordance could be because sizing and methylation analysis of all alleles that also have the microdeletion with the AmlideX primer binding sites (exclusively unmethylated by southern blot) being missed, leading to over-estimation of methylation by AmplideX for this case.
FREE2 Methylation, FMR1 mRNA Analyses and Testing for Other Genetic Causes of Ataxia
Increase in FREE2 methylation has been previously linked to FMR1 protein (FMRP) deficiency and the severity of cognitive impairment in FM males and females with FXS [Godler et al., 2012] . In this male, blood and saliva showed mean 
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